In8bio Inc (INAB) Stock Analysis

In8bio Inc (INAB) is a publicly traded company in the HEALTHCARE sector. It trades at $1.56, carries a market capitalization of $18.41M. This page summarizes the public market data, fundamentals, and frequently asked questions for INAB, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.56
• Market Cap: $18.41M
• EPS: $-2.54
• 52-Week High: $4.17
• 52-Week Low: $1.17

Market Sentiment

In8bio Inc currently has a Bullish sentiment score of 0.20.

About In8bio Inc

In8bio, Inc. is a New York-based clinical-stage biotechnology company focused on advancing innovative therapies for cancer treatment through the development of genetically modified gamma-delta T cells. By leveraging its expertise in both autologous and allogeneic cell therapies, the company is effectively targeting solid tumors and positioning itself as a leader in the immuno-oncology sector. With a strong pipeline of proprietary treatments and a dedication to addressing significant unmet nee...

GNG Research Analysis

GNG Research scores In8bio Inc (INAB) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for INAB.

Frequently Asked Questions

Does INAB pay dividends?

In8bio Inc (INAB) does not currently pay a regular dividend.

What is INAB's market cap?

In8bio Inc (INAB) has a market capitalization of $18.41M with a current stock price of $1.56.